Effects of DPP-?inhibitor and /or metformin combination on type 2 diabetes

Effects of DPP-?inhibitor and /or metformin combination on adipokine, inflammation and vascular endothelial function in type 2 diabetes patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001331

Enrollment

Unknown

Registered

2011-02-16

Start date

2011-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Group A:DPP-?inhibitor tablet 5mg qd

Group B:Metformin tablet 0.5 tid

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 75 years old; 2. Newly diagnosed type 2 diabetes or poor controlled glycemia with metaformin alone or other one kind antidiabetic diabetes drug; 3. HbA1c between 7%-10%, BMI less than 35.

Exclusion criteria

Exclusion criteria: 1. Impaired hepatic function with ALT higher than 3 X upper limit of normal; 2. Impaired renal function with serum Cr higher than 1.5 mg/dl; 3. Myocardial infarction, stroke or TIA within 6 months prior to informed consent; 4. Use of insulin, rosiglitazone or piogalitazone, or GLP-1 analogue within 3months prior to informed consent.

Design outcomes

Primary

Measure	Time frame
adipokine;inflammation;vascular endothelial function;	—

Countries

China

Contacts

Public ContactGangyi Yang

gangyiyang@yahoo.com.cn+86 23 68485216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026